Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.

The nasal spray Spravato, which is made from the drug ... neurotransmitter and can reduce symptoms in as little as 24 hours. Johnson & Johnson said that because there are risks of "serious adverse ...

The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions ... in their symptoms as early as 24 hours without the need for daily oral ...

This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato ... in depressive symptoms as early as 24 hours and at 28 days—without the ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults ... depressive symptoms beginning about 24 hours after treatment and lasting through at least ...

21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant ... depressive symptoms as early as 24 hours and at 28 days -- without ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray as the first ... symptoms as early as 24 hours and at 28 days ...

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

The nasal spray can be given to people who haven ... said that patients taking Spravato could start to see results in 24 hours. It’s already been given to 140,000 patients worldwide.

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults ... as early as 24 hours and at 28 days -- without ...